Tauopathy Comparison Matrix

📖 Wiki Page

disease1790 wordssynced 2026-04-02

Tauopathy Comparison Matrix

Overview

This page provides a comprehensive comparative analysis of the major tauopathies—Alzheimer's Disease (AD), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), and Frontotemporal Lobar Degeneration with tau pathology (FTLD-tau). These disorders share the common feature of abnormal tau protein accumulation but differ significantly in their clinical presentations, anatomical distributions, tau isoforms involved, and genetic risk factors[@goedert2022].

flowchart TD subgraph Tauopathies ["Major Tauopathies"] AD["Alzheimer's Disease"] CBD["Corticobasal Degeneration"] PSP["Progressive Supranuclear Palsy"] FTLD["FTLD-tau"] end subgraph CommonFeatures ["Shared Pathological Features"] TA["Tau Protein Misfolding"] PH["Hyperphosphorylation"] AG["Aggregation into Fibrils"] NL["Neuronal Loss"] end TA --> PH --> AG --> NL AD --> TA CBD --> TA PSP --> TA FTLD --> TA

Tau Isoforms and Biochemistry

Isoform Composition

The tau protein exists in six isoforms in the adult human brain, generated by alternative splicing of exons 2, 3, and 10 in the [MAPT](/genes/mapt) gene. The key distinction is between three-repeat (3R) and four-repeat (4R) tau isoforms, determined by the inclusion or exclusion of exon 10[@wang2016].

...

Tauopathy Comparison Matrix

Overview

Mermaid diagram (expand to render)

Tau Isoforms and Biochemistry

Isoform Composition

| Disease | Primary Tau Isoform | 3R:4R Ratio | Key Distinction |
|---------|-------------------|--------------|-----------------|
| Alzheimer's Disease | Mixed 3R + 4R | 1:1 | Both 3R and 4R tau in NFTs |
| CBD | 4R tau | 0:1 | Exclusively 4R tau |
| PSP | 4R tau | 0:1 | Exclusively 4R tau |
| FTLD-tau | Variable (mutation-dependent) | Variable | Depends on MAPT mutation |

Tau Filament Structures (Cryo-EM)

Recent cryo-electron microscopy studies have revealed distinct tau filament folds in each tauopathy, supporting the tau strain hypothesis[@fitzpatrick2017]:

| Disease | Filament Type | Structural Features |
|---------|--------------|---------------------|
| AD | Paired Helical Filaments (PHFs) | Classic helical structure, cross-β sheet |
| CBD | CBD Fold | Distinct helical filament architecture |
| PSP | PSP Fold (Globose NFTs) | 4R tau filaments, compact tangles |
| FTLD-tau | Variable | Depends on underlying mutation |

Post-Translational Modifications

| Modification | AD | CBD | PSP | FTLD-tau |
|--------------|-----|-----|-----|----------|
| Hyperphosphorylation | +++ | +++ | +++ | ++ |
| Acetylation | ++ | + | + | ++ |
| Truncation | ++ | + | + | ++ |
| Glycation | + | - | - | + |
| Ubiquitination | ++ | + | + | ++ |

Affected Brain Regions

Regional Distribution

| Brain Region | AD | CBD | PSP | FTLD-tau |
|--------------|-----|-----|-----|----------|
| Frontal Cortex | Late (neocortex) | ++ (early) | + (premotor) | +++ (early) |
| Parietal Cortex | Late | ++ | - | ++ |
| Temporal Cortex | Early (entorhinal) | + | - | ++ |
| Occipital Cortex | Late | - | - | + |
| Hippocampus | +++ (early) | - | - | + |
| Basal Ganglia | + | +++ | +++ | ++ |
| Substantia Nigra | + | +++ | +++ | + |
| Brainstem | + (later) | + | +++ | + |
| Cerebellum | - | + (dentate nucleus) | + (dentate) | - |

Neuroanatomical Progression Patterns

Alzheimer's Disease:

Braak stages I-II: Transentorhinal cortex (preclinical)
Braak stages III-IV: Limbic system (amnesitic MCI)
Braak stages V-VI: Isocortex (severe dementia)

Corticobasal Degeneration:

Motor and premotor cortex (early)
Basal ganglia (substantia nigra, globus pallidus)
Brainstem nuclei

Progressive Supranuclear Palsy:

Substantia nigra (early)
Globus pallidus
Brainstem (red nucleus, superior colliculus)
Frontal eye fields

FTLD-tau:

Frontal and anterior temporal lobes (early)
Amygdala and basal forebrain
Variable subcortical involvement

Mermaid diagram (expand to render)

Clinical Features

Core Diagnostic Symptoms

| Feature | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Cognitive Decline | ++ (memory prominent) | ++ (executive) | + (executive) | +++ (executive/social) |
| Motor Symptoms | + (late) | +++ (asymmetric) | +++ (akinesia) | + (if present) |
| Eye Movement | - | - | +++ (vertical gaze palsy) | - |
| Postural Instability | - | ++ | +++ (falls early) | - |
| Language | + (anomia) | + | - | +++ (aphasia) |
| Behavior | + (late) | + | + | +++ (early) |
| Asymmetry | - | +++ | - | -/+ |

Disease-Specific Hallmarks

Alzheimer's Disease:

Progressive episodic memory loss
Anterograde amnesia
Word-finding difficulties (anomia)
Visuospatial impairment (later)
Behavioral changes in moderate to severe stages

Corticobasal Degeneration:

Asymmetric parkinsonism
Apraxia (especiallyideomotor)
Cortical sensory loss
Alien limb phenomenon
Myoclonus (sometimes)

Progressive Supranuclear Palsy:

Vertical supranuclear gaze palsy (downward > upward)
Early postural instability with falls
Akinesia and bradykinesia
Axial rigidity
Dysarthria and dysphagia

FTLD-tau:

Behavioral variant: Disinhibition, apathy, compulsions
Primary progressive aphasia: Nonfluent or semantic
Executive dysfunction
Relative memory preservation early

Clinical Progression

| Metric | AD | CBD | PSP | FTLD-tau |
|--------|-----|-----|-----|----------|
| Typical Onset (years) | 65-80 | 50-70 | 60-70 | 45-65 |
| Disease Duration (years) | 8-15 | 5-10 | 5-10 | 6-12 |
| Survival from Onset | 8-12 years | 6-8 years | 5-7 years | 6-11 years |

Genetic Risk Factors

Gene Associations

| Gene | AD | CBD | PSP | FTLD-tau |
|------|-----|-----|-----|----------|
| MAPT | Risk (H1 haplotype) | ++ (H1) | ++ (H1) | ++ (mutations) |
| APOE | ++ (ε4 risk) | - | - | - |
| GRN | - | + | - | ++ (mutations) |
| LRRK2 | + (risk) | + | + (risk) | - |
| C9orf72 | - | - | - | ++ (expansion) |
| TARDBP | - | - | - | + |
| VCP | - | - | - | + |

MAPT H1 Haplotype

The H1 haplotype of [MAPT](/genes/mapt) is a significant risk factor for sporadic tauopathies[@connor2004]:

H1/H1 genotype: Increases risk for CBD, PSP, and AD
H1/H2 genotype: May be protective
Odds ratio for PSP: ~4-5
Odds ratio for CBD: ~3-4

FTLD-tau Specific Mutations

Specific [MAPT](/genes/mapt) mutations cause familial FTLD-tau:

| Mutation | Exon | Effect | Phenotype |
|----------|------|--------|-----------|
| P301L | 10 | Increased aggregation | CBD/PSP/FTD |
| P301S | 10 | Increased aggregation | CBD/FTD |
| V337M | 12 | Altered splicing | FTD |
| R406W | 13 | Reduced binding | FTD/AD-like |

Therapeutic Approaches

Current Treatment Strategies

| Approach | AD | CBD | PSP | FTLD-tau |
|----------|-----|-----|-----|----------|
| Symptomatic | Donepezil, memantine | Limited | Limited | Limited |
| Tau Aggregation Inhibitors | In trials | Preclinical | Preclinical | Preclinical |
| Immunotherapy | Phase 2/3 | Preclinical | Preclinical | Preclinical |
| Kinase Inhibitors | GSK-3β in trials | Preclinical | Preclinical | Preclinical |

Clinical Trials Landscape

Active/Recent Anti-Tau Trials for AD:

Gosuranemab (Biogen) — Phase II completed
Semorinemab (Roche) — Phase II
Tilavonemab (AbbVie) — Phase II
JNJ-63761257 (Janssen) — Phase I

Disease-Modifying Approaches:

Microtubule stabilizers (e.g., davunetide)
Tau antisense oligonucleotides
Gene therapy approaches

Symptomatic Management

| Symptom | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Cognitive | Cholinesterase inhibitors | None | None | None |
| Motor | None | Dopamine agonists | Limited | None |
| Behavioral | Antidepressants | Antidepressants | Antidepressants | SSRIs |
| Sleep | Melatonin | Clonazepam | Melatonin | Varies |

Biomarkers

CSF Biomarkers

| Marker | AD | CBD | PSP | FTLD-tau |
|--------|-----|-----|-----|----------|
| Total tau | Elevated ++ | Normal/+ | Normal/+ | Normal/+ |
| p-tau181 | Elevated +++ | Normal/+ | Normal/+ | Normal/+ |
| p-tau217 | Elevated +++ | Normal | Normal | Normal |
| p-tau231 | Elevated ++ | Normal | Normal | Normal |
| NfL | Elevated ++ | Elevated ++ | Elevated ++ | Elevated + |

PET Imaging

| Tracer | Target | AD | CBD | PSP | FTLD-tau |
|--------|--------|-----|-----|-----|----------|
| ^18F-AV-1451 | PHF tau | ++ | + | + | + |
| ^18F-MK-6240 | PHF tau | ++ | + | + | + |
| ^18F-GT1 | 4R tau | - | ++ | ++ | Variable |
| ^11C-PBB3 | All tau | ++ | ++ | ++ | ++ |

Differential Diagnosis

Key Distinguishing Features

| Feature | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Memory loss | First/dominant | Late/mild | Late/mild | Late/mild |
| Motor onset | Late | Early (asymmetric) | Early (symmetric) | Variable |
| Eye movements | Normal | Normal | VSGP | Normal |
| Speech | Anomia | Dysarthria | Hypophonia | Aphasia |
| Personality | Preserved | Preserved | Apathy | Disinhibited |

Clinical Criteria

NINDS-SPSP Criteria for PSP:

Vertical supranuclear gaze palsy
Postural instability with falls within first year
Akinesia with bradykinesia

Core Clinical Features for CBD:

Asymmetric parkinsonism
Apraxia
Cortical sensory loss
Alien limb

Cross-References

[Tau Protein](/proteins/tau) — Main tau protein page
[4R Tau](/proteins/4r-tau) — Four-repeat tau isoform
[3R Tau](/proteins/3r-tau) — Three-repeat tau isoform
[Phospho-Tau](/proteins/phospho-tau) — Phosphorylated tau
[p-Tau181](/proteins/p-tau181-protein) — AD biomarker
[p-Tau217](/proteins/p-tau217-protein) — AD biomarker
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[4R Tauopathies Genetics](/diseases/4r-tauopathies-genetics)
[MAPT Gene](/genes/mapt)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology)

References

[Goedert M, et al., Tauopathies: Update and perspective. Brain Res Bull. 2022;182:34-48 (2022)](https://pubmed.ncbi.nlm.nih.gov/35151579/)

[Unknown, Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21 (2016)](https://pubmed.ncbi.nlm.nih.gov/26634968/)

[Fitzpatrick M, et al., Cryo-EM structures of tau filaments from Alzheimer's disease brain. Nature. 2017;547(7662):185-190 (2017)](https://pubmed.ncbi.nlm.nih.gov/28678775/)

[Connor L, et al., MAPT haplotype H1 is associated with increased risk of PSP and CBD. Neurology. 2004;63(1):166-167 (2004)](https://pubmed.ncbi.nlm.nih.gov/15249631/)

[Williams DR, et al., Characteristics of two distinct clinical phenotypes in PSP. Brain. 2005;128(Pt 6):1247-1258 (2005)](https://pubmed.ncbi.nlm.nih.gov/15737937/)

[Litvan I, et al., Accuracy of clinical diagnosis of progressive supranuclear palsy. Neurology. 1996;46(4):922-930 (1996)](https://pubmed.ncbi.nlm.nih.gov/8780075/)

[Alexander SK, et al., Pathological relationships between CBD and PSP. Brain. 2014;137(Pt 7):1927-1938 (2014)](https://pubmed.ncbi.nlm.nih.gov/24836286/)

[Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2011;12(2):95-107 (2011)](https://pubmed.ncbi.nlm.nih.gov/21252998/)

[Choi W, et al., Tau PET imaging in atypical parkinsonism. Mov Disord. 2022;37(2):288-299 (2022)](https://pubmed.ncbi.nlm.nih.gov/34751467/)

[Hogan DB, et al., The progression of FTLD. Nat Rev Neurol. 2023;19(10):585-598 (2023)](https://pubmed.ncbi.nlm.nih.gov/37644123/)

📖 View canonical wiki page →

Tauopathy Comparison Matrix

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tau Filament Structures (Cryo-EM)

Post-Translational Modifications

Affected Brain Regions

Regional Distribution

Neuroanatomical Progression Patterns

Clinical Features

Core Diagnostic Symptoms

Disease-Specific Hallmarks

Clinical Progression

Genetic Risk Factors

Gene Associations

MAPT H1 Haplotype

FTLD-tau Specific Mutations

Therapeutic Approaches

Current Treatment Strategies

Clinical Trials Landscape

Symptomatic Management

Biomarkers

CSF Biomarkers

PET Imaging

Differential Diagnosis

Key Distinguishing Features

Clinical Criteria

Cross-References

Related Pages

References